TY - JOUR
T1 - Hepatitis C virus treatment in the real world
T2 - Optimising treatment and access to therapies
AU - Zoulim, Fabien
AU - Liang, T. Jake
AU - Gerbes, Alexander L.
AU - Aghemo, Alessio
AU - Deuffic-Burban, Sylvie
AU - Dusheiko, Geoffrey
AU - Fried, Michael W.
AU - Pol, Stanislas
AU - Rockstroh, Jürgen Kurt
AU - Terrault, Norah A.
AU - Wiktor, Stefan
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Chronic HCV infections represent a major worldwide public health problem and are responsible for a large proportion of liver related deaths, mostly because of HCV-associated hepatocellular carcinoma and cirrhosis. The treatment of HCV has undergone a rapid and spectacular revolution. In the past 5 years, the launch of direct acting antiviral drugs has seen sustained virological response rates reach 90% and above for many patient groups. The new treatments are effective, well tolerated, allow for shorter treatment regimens and offer new opportunities for previously excluded groups. This therapeutic revolution has changed the rules for treatment of HCV, moving the field towards an interferon-free era and raising the prospect of HCV eradication. This manuscript addresses the new challenges regarding treatment optimisation in the real world, improvement of antiviral efficacy in 'hard-to-treat' groups, the management of patients whose direct acting antiviral drug treatment was unsuccessful, and access to diagnosis and treatment in different parts of the world.
AB - Chronic HCV infections represent a major worldwide public health problem and are responsible for a large proportion of liver related deaths, mostly because of HCV-associated hepatocellular carcinoma and cirrhosis. The treatment of HCV has undergone a rapid and spectacular revolution. In the past 5 years, the launch of direct acting antiviral drugs has seen sustained virological response rates reach 90% and above for many patient groups. The new treatments are effective, well tolerated, allow for shorter treatment regimens and offer new opportunities for previously excluded groups. This therapeutic revolution has changed the rules for treatment of HCV, moving the field towards an interferon-free era and raising the prospect of HCV eradication. This manuscript addresses the new challenges regarding treatment optimisation in the real world, improvement of antiviral efficacy in 'hard-to-treat' groups, the management of patients whose direct acting antiviral drug treatment was unsuccessful, and access to diagnosis and treatment in different parts of the world.
UR - http://www.scopus.com/inward/record.url?scp=84947554940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947554940&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2015-310421
DO - 10.1136/gutjnl-2015-310421
M3 - Article
C2 - 26449729
AN - SCOPUS:84947554940
SN - 0017-5749
VL - 64
SP - 1824
EP - 1833
JO - Gut
JF - Gut
IS - 11
ER -